Pharmaceutical Group – Talk Bio

Actionable Insights Powered by AI

Madrigal Pharmaceuticals Inks up to $2B Deal with CSPC for Preclinical Oral GLP-1, Plans Combination with Rezdiffra for MASH

1 month ago talkbio0Tagged Combined Modality Therapy, global license agreement, GZMH gene, Madrigal Pharmaceuticals, MASH, milestone payments, oral small molecule, Pharmaceutical Group, preclinical drug, Product containing glucagon-like peptide 1 receptor agonist (product), Rezdiffra

Madrigal Pharmaceuticals; CSPC Pharmaceutical Group; GLP-1 receptor agonist; SYH2086; Rezdiffra; MASH; oral small molecule; preclinical drug; global license agreement; combination therapy; milestone payments

AstraZeneca Invests $2 Billion in CSPC’s Lipid-Lowering Therapy

11 months ago talkbio0Tagged AstraZeneca, Cardiovascular Diseases, Dosage Forms, GZMH gene, Investments, Lipid-lowering therapy, Lp(a ) disruptor, Pharmaceutical Group

AstraZeneca, CSPC Pharmaceutical Group, lipid-lowering therapy, Lp(a) disruptor, cardiovascular disease, pharmaceutical investment